Invitae Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Invitae stock.
View analyst ratings for Invitae or view top-rated stocks.

Wall Street analysts have given Invitae a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Invitae wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Invitae is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Invitae.

Invitae Co. (NYSE:NVTA) released its quarterly earnings results on Tuesday, February, 16th. The medical research company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.08. The medical research company had revenue of $100.43 million for the quarter, compared to analysts' expectations of $97.87 million. Invitae had a negative net margin of 183.50% and a negative trailing twelve-month return on equity of 81.19%.
View Invitae's earnings history.

Invitae's stock was trading at $15.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVTA stock has increased by 146.5% and is now trading at $39.07.
View which stocks have been most impacted by COVID-19.

Invitae updated its FY 2021 After-Hours earnings guidance on Wednesday, February, 17th. The company provided EPS guidance of for the period. The company issued revenue guidance of $450 million, compared to the consensus revenue estimate of $488.37 million.

7 analysts have issued 12-month price objectives for Invitae's shares. Their forecasts range from $35.00 to $65.00. On average, they anticipate Invitae's share price to reach $49.33 in the next twelve months. This suggests a possible upside of 26.3% from the stock's current price.
View analysts' price targets for Invitae or view top-rated stocks among Wall Street analysts.

59 employees have rated Invitae CEO Sean George on Glassdoor.com. Sean George has an approval rating of 87% among Invitae's employees.

Some companies that are related to Invitae include Laboratory Co. of America (LH), Quest Diagnostics (DGX), Guardant Health (GH), Natera (NTRA), Elekta AB (publ) (EKTAY), CareDx (CDNA), Veracyte (VCYT), Burning Rock Biotech (BNR), Fulgent Genetics (FLGT), Genetron (GTH), Castle Biosciences (CSTL), DermTech (DMTK), RadNet (RDNT), Personalis (PSNL) and Renalytix AI (RNLX).
View all of NVTA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), The Trade Desk (TTD), Shopify (SHOP), salesforce.com (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Invitae's stock is owned by many different institutional and retail investors. Top institutional shareholders include Profit Investment Management LLC (0.07%), OTA Financial Group L.P. (0.03%), Phoenix Wealth Advisors (0.01%), Carnegie Capital Asset Management LLC (0.01%), AdvisorNet Financial Inc (0.00%) and Pacer Advisors Inc. (0.00%). Company insiders that own Invitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Randal W Scott, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for Invitae.

NVTA stock was sold by a variety of institutional investors in the last quarter, including Profit Investment Management LLC, Phoenix Wealth Advisors, and Pacer Advisors Inc.. Company insiders that have sold Invitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for Invitae or view top insider-selling stocks.

NVTA stock was purchased by a variety of institutional investors in the last quarter, including OTA Financial Group L.P., Carnegie Capital Asset Management LLC, AdvisorNet Financial Inc, Baldwin Brothers Inc. MA, and Westside Investment Management Inc..
View insider buying and selling activity for Invitae or or view top insider-buying stocks.

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVTA stock can currently be purchased for approximately $39.07.

Invitae has a market capitalization of $7.68 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.

Invitae employs 2,100 workers across the globe.

The official website for Invitae is www.invitae.com.

Invitae is headquartered at 1400 16th Street, SAN FRANCISCO CA, 94103.

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]